Hepatitis b virus (HBVr) reactivation may occur in patients treated with immunosuppressive therapy and chemotherapy. Therefore, in the current biological age, it is important for physicians to understand the risk of hepatitis B virus reactivation in patients with autoimmune disease undergoing anti-cytokine therapy.